Pharmacokinetics of CsA during the switch from continuous intravenous infusion to oral administration after allogeneic hematopoietic stem cell transplantation.
We investigated the serial changes in the blood CsA concentration during the switch from continuous intravenous infusion to twice-daily oral administration in allogeneic hematopoietic stem cell transplant recipients (n=12). The microemulsion form of CsA, Neoral, was started at twice the last dose in intravenous infusion in two equally divided doses. The area under the concentration-time curve during oral administration (AUC(PO)) was significantly higher than the AUC during intravenous infusion (AUC(IV)) (median 7508 vs 6705 ng/ml x h, P=0.050). The median bioavailability of Neoral, defined as (AUC(PO)/DOSE(PO)) divided by (AUC(IV)/DOSE(IV)), was 0.685 (range, 0.45-1.04). Concomitant administration of oral voriconazole (n=4) significantly increased the bioavailability of Neoral (median 0.87 vs 0.54, P=0.017), probably due to the inhibition of gut CYP3A4 by voriconazole. Although the conversion from intravenous to oral administration of CsA at a ratio of 1:2 seemed to be appropriate in most patients, a lower conversion ratio may be better in patients taking oral voriconazole. To obtain a similar AUC, the target trough concentrations during twice-daily oral administration should be halved compared with the target concentration during continuous infusion.
Kimura
S
S
Division of Hematology, Saitama Medical Center, Jichi Medical University, Saitama, Japan.
Oshima
K
K
Okuda
S
S
Sato
K
K
Sato
M
M
Terasako
K
K
Nakasone
H
H
Kako
S
S
Yamazaki
R
R
Tanaka
Y
Y
Tanihara
A
A
Higuchi
T
T
Nishida
J
J
Kanda
Y
Y
D000284:Administration, Oral; D000293:Adolescent; D000328:Adult; D000935:Antifungal Agents; D019540:Area Under Curve; D001682:Biological Availability; D016572:Cyclosporine / Q000493:pharmacokinetics*; D004357:Drug Synergism; D005260:Female; D006086:Graft vs Host Disease; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects* / Q000379:methods; D006801:Humans; D007166:Immunosuppressive Agents; D007262:Infusions, Intravenous; D008297:Male; D008875:Middle Aged; D011743:Pyrimidines / Q000627:therapeutic use; D014184:Transplantation, Homologous; D016896:Treatment Outcome; D014230:Triazoles / Q000627:therapeutic use; D065819:Voriconazole; D055815:Young Adult
D000935:Antifungal Agents; D007166:Immunosuppressive Agents; D011743:Pyrimidines; D014230:Triazoles; D016572:Cyclosporine; D065819:Voriconazole